在社区医疗环境中使用秋水仙碱治疗新冠病毒病 - Suppr

Treating COVID-19 with colchicine in community healthcare setting.

作者信息

Della-Torre Emanuel, Della-Torre Fabrizio, Kusanovic Marija, Scotti Raffaella, Ramirez Giuseppe Alvise, Dagna Lorenzo, Tresoldi Moreno

机构信息

Università Vita-Salute San Raffaele, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Centro Medico Sant'Agostino, Milan, Italy.

出版信息

Clin Immunol. 2020 Aug;217:108490. doi: 10.1016/j.clim.2020.108490. Epub 2020 May 31.

DOI:10.1016/j.clim.2020.108490

PMID:32492478

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7261351/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/214e/7261351/4b5815e71fc1/gr1_lrg.jpg

相似文献

Treating COVID-19 with colchicine in community healthcare setting.在社区医疗环境中使用秋水仙碱治疗新冠病毒病

Clin Immunol. 2020 Aug;217:108490. doi: 10.1016/j.clim.2020.108490. Epub 2020 May 31.

SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.严重急性呼吸综合征冠状病毒 2 感染和 Nlrp3 炎性小体过度激活作为细胞因子“风暴”的触发因素和造血干细胞损伤的危险因素。

Leukemia. 2020 Jul;34(7):1726-1729. doi: 10.1038/s41375-020-0887-9. Epub 2020 Jun 1.

A plea for the pathogenic role of immune complexes in severe Covid-19.关于免疫复合物在重症新型冠状病毒肺炎中致病作用的呼吁。

Clin Immunol. 2020 Aug;217:108493. doi: 10.1016/j.clim.2020.108493. Epub 2020 Jun 8.

After 62 years of regulating immunity, dexamethasone meets COVID-19.地塞米松调控免疫 62 年后迎击 COVID-19。

Nat Rev Immunol. 2020 Oct;20(10):587-588. doi: 10.1038/s41577-020-00421-x.

Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2-associated multisystem inflammatory syndrome.一名患有新型冠状病毒2型相关多系统炎症综合征儿童的白细胞红细胞增多症和浆细胞样淋巴细胞

Blood. 2020 Aug 13;136(7):914. doi: 10.1182/blood.2020007132.

Successful use of methylprednisolone for treating severe COVID-19.甲基泼尼松龙成功用于治疗重症新型冠状病毒肺炎。

J Allergy Clin Immunol. 2020 Aug;146(2):325-327. doi: 10.1016/j.jaci.2020.05.021. Epub 2020 May 29.

Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.重症新型冠状病毒肺炎、内稳态与有效糖皮质激素治疗的“意外”效果

Clin Immunol. 2020 Oct;219:108550. doi: 10.1016/j.clim.2020.108550. Epub 2020 Jul 31.

Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.新型冠状病毒肺炎的新兴治疗方法：包括药物过敏在内的药物不良反应。

J Allergy Clin Immunol. 2020 Oct;146(4):786-789. doi: 10.1016/j.jaci.2020.07.008. Epub 2020 Jul 22.

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.用雷帕霉素靶向T细胞衰老和细胞因子风暴以预防COVID-19的严重进展。

Clin Immunol. 2020 Jul;216:108464. doi: 10.1016/j.clim.2020.108464. Epub 2020 May 13.

COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.新型冠状病毒肺炎、肺肥大细胞、细胞因子风暴以及木犀草素的有益作用

Biofactors. 2020 May;46(3):306-308. doi: 10.1002/biof.1633. Epub 2020 Apr 27.

引用本文的文献

Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach.新冠疫苗有效性和免疫原性面临的挑战：一项采用系统方法的叙述性综述

Vaccines (Basel). 2025 Jul 24;13(8):789. doi: 10.3390/vaccines13080789.

[Colchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review].[秋水仙碱：老朋友对COVID-19中风湿病学的看法：一项范围综述]

Rev Colomb Reumatol. 2022 Jun;29:S35-S47. doi: 10.1016/j.rcreu.2021.02.002. Epub 2021 Mar 27.

Colchicine and/or Naltrexone for Hospitalized COVID-19 Patients Not Requiring High Levels of Ventilatory Support (COLTREXONE): A Prospective, Randomized, Open-Label Trial.用于不需要高水平通气支持的住院COVID-19患者的秋水仙碱和/或纳曲酮（COLTREXONE）：一项前瞻性、随机、开放标签试验。

Cureus. 2024 May 15;16(5):e60364. doi: 10.7759/cureus.60364. eCollection 2024 May.

Does SARS-CoV-2 Induce IgG4 Synthesis to Evade the Immune System?SARS-CoV-2 是否诱导 IgG4 合成以逃避免疫系统？

Biomolecules. 2023 Sep 1;13(9):1338. doi: 10.3390/biom13091338.

Neutrophils in COVID-19: recent insights and advances.新型冠状病毒肺炎中的中性粒细胞：最新的认识和进展。

Virol J. 2023 Aug 2;20(1):169. doi: 10.1186/s12985-023-02116-w.

COVID-19 and candiduria: an investigation of the risk factors and immunological aspects.COVID-19 和念珠菌尿症：风险因素和免疫学方面的研究。

Braz J Microbiol. 2023 Sep;54(3):1783-1793. doi: 10.1007/s42770-023-01042-x. Epub 2023 Jul 5.

Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology.炎症小体：COVID-19 病理生理学地平线上的一颗冉冉升起的新星。

Front Immunol. 2023 May 12;14:1185233. doi: 10.3389/fimmu.2023.1185233. eCollection 2023.

IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein.重复接种疫苗诱导产生的IgG4抗体可能会对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白产生免疫耐受。

Vaccines (Basel). 2023 May 17;11(5):991. doi: 10.3390/vaccines11050991.

Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial.秋水仙碱治疗中度 COVID-19 患者的疗效：一项双盲、随机、安慰剂对照试验。

PLoS One. 2022 Nov 16;17(11):e0277790. doi: 10.1371/journal.pone.0277790. eCollection 2022.

FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.FRAGILE-COLCOVID19：一项基于在老年护理机构中的 COVID-19 老年患者中早期使用秋水仙碱和泼尼松口服联合治疗的临床试验。

Clin Drug Investig. 2022 Nov;42(11):949-964. doi: 10.1007/s40261-022-01201-2. Epub 2022 Sep 29.

本文引用的文献

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.白细胞介素 6 阻断剂沙利鲁单抗治疗伴有全身炎症反应综合征的重症 COVID-19 肺炎：一项开放标签队列研究。

Ann Rheum Dis. 2020 Oct;79(10):1277-1285. doi: 10.1136/annrheumdis-2020-218122. Epub 2020 Jul 3.

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。

Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.托珠单抗治疗重症 COVID-19 患者的疗效和安全性：一项单中心回顾性队列研究。

Eur J Intern Med. 2020 Jun;76:43-49. doi: 10.1016/j.ejim.2020.05.021. Epub 2020 May 22.

COVID-19: Immunology and treatment options.新型冠状病毒肺炎：免疫学与治疗选择。

Clin Immunol. 2020 Jun;215:108448. doi: 10.1016/j.clim.2020.108448. Epub 2020 Apr 27.

COVID-19 pathophysiology: A review.新型冠状病毒肺炎的病理生理学：综述。

Clin Immunol. 2020 Jun;215:108427. doi: 10.1016/j.clim.2020.108427. Epub 2020 Apr 20.

Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎

Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.

COVID-19 and Italy: what next?COVID-19 和意大利：下一步如何？

Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》

JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.

Colchicine as a new therapeutic option for antithyroid arthritis syndrome.秋水仙碱作为抗甲状腺关节炎综合征的一种新的治疗选择。

Rheumatology (Oxford). 2020 Jun 1;59(6):1452-1453. doi: 10.1093/rheumatology/kez547.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treating COVID-19 with colchicine in community healthcare setting.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献